Want to see IVA full AI Analyst Report?
Top Page
Inventiva
(NASDAQ:IVA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.00
▼(-36.03% Downside)
Action:Reiterated
Date:10/14/26
The score is primarily held down by weak financial performance (persistent large losses, rising cash burn, and negative equity) and bearish technical signals (price below major moving averages and negative MACD). Offsetting this, the latest earnings call conveyed solid progress toward the NATiV3 Phase III readout and improved financing/runway visibility, but these positives remain contingent on upcoming clinical results and tolerability/approval risks.
Positive Factors
Late-stage clinical progress
A large, fully recruited Phase III study represents meaningful development progress and provides a defined near-term catalyst for the company’s lead asset. If results confirm earlier findings, Inventiva could advance toward an NDA filing and strengthen its position in the MASH treatment market.
Negative Factors
Persistent operating losses
Continued negative operating and free cash flow shows that Inventiva remains dependent on external financing to fund research and development. Rising cash burn can shorten the runway, constrain investment choices, and increase the importance of successful clinical and financing outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical progress
A large, fully recruited Phase III study represents meaningful development progress and provides a defined near-term catalyst for the company’s lead asset. If results confirm earlier findings, Inventiva could advance toward an NDA filing and strengthen its position in the MASH treatment market.
Read all positive factors
Inventiva (IVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$783.91M
Dividend YieldN/A
Average Volume (3M)2.17M
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-99.61%
EPS Growth66.37%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding237,986,700
10 Day Avg. Volume3,359,356
30 Day Avg. Volume2,172,263
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-29.92
Price to Sales (P/S)193.76
P/FCF Ratio-8.58
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue690.08
Enterprise Value/Gross Profit-2.86K
Enterprise Value/Ebitda-6.20
Forecast
1Y Price Target
$15.50Price Target Upside230.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$3.74M
Inventiva Business Overview & Revenue Model
Company Description
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatoh...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Inventiva has historically not depended on recurring product sales; instead, it has financed operations primarily through (i) collaboration and licensing arrangements and (ii) capital raising. Under c...
Inventiva Earnings Call Summary
Earnings Call Date:Sep 28, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 31, 2027
Earnings Call Sentiment Positive
The call was strongly focused on progress toward the NATiV3 phase III readout, positive phase II-B efficacy, preparation for potential regulatory and commercial milestones, and a strengthened financial position. Management also addressed known tolerability considerations, including weight gain, edema, and hemoglobin decline, while withholding additional blinded phase III safety and efficacy details. The positive development, financing, and preparation updates significantly outweighed the disclosed challenges and uncertainties.Positive Updates
NATiV3 Phase III Trial Remains on Track
Inventiva remains on track to report NATiV3 top-line results in the fourth quarter of 2026. The last patient completed the final 72-week visit earlier in September 2026.
Negative Updates
Lanifibranor-Related Weight Gain and Fluid Retention
The phase II-B safety profile included weight gain, edema, and hemoglobin decline associated with partial PPAR gamma activation. The company described these effects as present but attenuated relative to full TZD-class gamma agonists.
Read all updates
Q2-2026 Updates
Positive
Negative
NATiV3 Phase III Trial Remains on Track
Inventiva remains on track to report NATiV3 top-line results in the fourth quarter of 2026. The last patient completed the final 72-week visit earlier in September 2026.
Read all positive updates
Company Guidance
Inventiva remains on track to report NATiV3 top-line data in the fourth quarter of 2026 after the last patient completed their final 72-week visit; the main cohort enrolled 1,009 participants with F2 or F3 fibrosis, and the trial was powered at 90%. Subject to positive phase III results, the company intends to file an NDA with the FDA in the first half of 2027, seek accelerated approval with the FDA and conditional approval with the EMA, and pursue a potential U.S. commercial launch in 2028; current financing provides cash runway until the end of the second quarter of 2027, extending to the start of the first quarter of 2028 assuming full exercise of Tranche 3 warrants and successful completion of Tranche C, while the company expects to initiate a confirmatory outcomes trial in cACLD and has not provided guidance on NATiV3 top-line details, edema over time, or future raises.Inventiva Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 4.48M | 9.20M | 17.48M | 12.18M | 4.19M |
| Gross Profit | -322.28K | 1.51M | 9.20M | 17.50M | 17.06M | 4.19M |
| EBITDA | -148.45M | -127.72M | -166.53M | -102.04M | -55.46M | ― |
| Net Income | -247.34M | -340.16M | -184.21M | -110.43M | -54.27M | -49.64M |
Balance Sheet | ||||||
| Total Assets | 251.11M | 248.88M | 118.97M | 69.56M | 116.00M | 121.98M |
| Cash, Cash Equivalents and Short-Term Investments | 166.06M | 99.27M | 96.56M | 27.34M | 87.78M | 86.55M |
| Total Debt | 66.63M | 59.40M | 54.33M | 37.49M | 34.51M | 10.12M |
| Total Liabilities | 192.13M | 277.91M | 225.61M | 101.59M | 70.53M | 33.12M |
| Stockholders Equity | 58.98M | -29.04M | -106.65M | -32.03M | 45.48M | 88.87M |
Cash Flow | ||||||
| Free Cash Flow | -113.51M | -101.22M | -86.26M | -82.15M | -45.49M | -48.16M |
| Operating Cash Flow | -113.15M | -100.98M | -85.93M | -81.61M | -44.93M | -47.63M |
| Investing Cash Flow | -44.47M | -127.93M | 8.74M | -7.73M | 8.87M | -1.79M |
| Financing Cash Flow | 203.37M | 232.00M | 145.59M | 29.08M | 37.27M | 25.45M |
Inventiva Technical Analysis
Negative
4.69
Price Trends
4.17
Negative
4.21
Negative
4.99
Negative
Market Momentum
-0.27
Positive
31.61
Neutral
8.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVA, the sentiment is Negative. The current price of 4.69 is above the 20-day moving average (MA) of 3.50, above the 50-day MA of 4.17, and below the 200-day MA of 4.99, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 31.61 is Neutral, neither overbought nor oversold. The STOCH value of 8.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVA.
Inventiva Risk Analysis
Inventiva disclosed 83 risk factors in its most recent earnings report. Inventiva reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Through the Royalty Certificates, we transferred to the holders thereof rights to receive certain payments in connection with potential future net sales of lanifibranor, if any, which may reduce our ability to realize potential future revenue from such sales. Q4, 2023
Inventiva Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.60B | -19.86 | -40.51% | ― | 34.52% | 41.20% | |
62 Neutral | $1.83B | -12.19 | -35.42% | ― | -3.28% | 61.09% | |
60 Neutral | $2.51B | -20.42 | -26.01% | ― | ― | -4.40% | |
58 Neutral | $924.75M | -2.92 | -207.18% | ― | -7.27% | -48.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.87B | -19.32 | 81.78% | ― | 100.27% | 39.90% | |
47 Neutral | $783.91M | -4.99 | -1625.48% | ― | -99.61% | 66.37% |
* Healthcare Sector Average
IVA
Inventiva
2.87
-2.09
-42.14%
IOVA
Iovance Biotherapeutics
14.50
12.38
583.96%
KURA
Kura Oncology
9.83
0.21
2.18%
URGN
Urogen Pharma
38.26
21.61
129.79%
MRVI
Maravai Lifesciences Holdings
6.53
3.30
102.17%
MBX
MBX Biosciences, Inc.
49.00
35.48
262.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.